Patents by Inventor Lars Holm Damgaard

Lars Holm Damgaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SEMAGLUTIDE FOR USE IN MEDICINE
    Publication number: 20250152672
    Abstract: The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.
    Type: Application
    Filed: January 15, 2025
    Publication date: May 15, 2025
    Inventors: Morten Hansen, Martin Linder, Carl Richard Torstenson, Mads Sundby Palle, Lars Holm Damgaard
  • Semaglutide in medical therapy
    Patent number: 12295988
    Abstract: The present invention relates to semaglutide for use in weight management.
    Type: Grant
    Filed: August 30, 2024
    Date of Patent: May 13, 2025
    Assignee: Novo Nordisk A/S
    Inventors: Lars Holm Damgaard, Soeren Oestergaard Hardt-Lindberg, Thomas Hansen
  • SEMAGLUTIDE FOR USE IN MEDICINE
    Publication number: 20240075106
    Abstract: The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.
    Type: Application
    Filed: October 24, 2023
    Publication date: March 7, 2024
    Inventors: Morten Hansen, Martin Linder, Carl Richard Torstenson, Mads Sundby Palle, Lars Holm Damgaard
  • SEMAGLUTIDE FOR USE IN MEDICINE
    Publication number: 20230023012
    Abstract: The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.
    Type: Application
    Filed: September 20, 2022
    Publication date: January 26, 2023
    Inventors: Morten Hansen, Martin Linder, Carl Richard Torstenson, Mads Sundby Palle, Lars Holm Damgaard
  • Semaglutide for use in medicine
    Patent number: 11478533
    Abstract: The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: October 25, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Morten Hansen, Martin Linder, Carl Richard Torstenson, Mads Sundby Palle, Lars Holm Damgaard
  • SEMAGLUTIDE FOR USE IN MEDICINE
    Publication number: 20210330748
    Abstract: The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.
    Type: Application
    Filed: May 13, 2020
    Publication date: October 28, 2021
    Inventors: Martin Linder, Mads Sundby Palle, Lars Holm Damgaard